Mentions
Profile
Position
Bill McConagha, a former Associate Chief Counsel and Assistant Commissioner at the US Food and Drug Administration (FDA), is a nationally recognized life sciences attorney who advises clients on a range of complex issues spanning the FDA-regulated product life cycle, from premarket development and clinical trials, through product launch, post-market safety reporting, and manufacturing requirements, including cGMP.
Bill draws on extensive federal government experience to represent companies across the FDA’s regulatory spectrum, including companies that manufacture or market pharmaceuticals, medical devices, biologics, foods, tobacco, and cosmetics. He helps clients navigate:
-
- FDA compliance, including preparing for and managing FDA inspections, responding to FDA 483s and warning letters, and complying with post-market safety requirements
- FDA regulatory issues, including pre- and post-market requirements and related commercial activities such as product importation and supply chain oversight
- FDA-related diligence and regulatory counsel, including negotiating representations and warranties, in corporate transactions
- Internal investigations involving clinical trial oversight, post-market safety reporting, and risk management
A recognized industry leader, he worked at FDA for 17 years in various high-level roles and served as a Health Policy Advisor on the Senate Committee on Health, Education, Labor, and Pensions (HELP).
During his tenure in public service, he received the following awards: Secretary’s Award for Distinguished Service, Department of Health and Human Services; Excellence in Legal Services, Office of the General Counsel, Department of Health and Human Services; Commissioner’s Special Recognition Award, FDA; Commissioner’s Special Citation, FDA; and the Director’s Award for Outstanding Service, FDA’s Office of Criminal Investigations.
Content supplied by Latham & Watkins LLP
Testimonials
Collated independently by Legal 500 research team.
‘Very strong knowledge in technology-driven life sciences, including unique aspects of such a regulated industry (FDA, etc.). Particularly strong knowledge and experience in public securities offerings in the life sciences.’
‘After my 35 years in the medical device industry and 3 IPOs, I believe Shayne Kennedy has more relevant experience than any other lawyer at any firm.’
Key clients
- 4D Molecular Therapeutics
- AbbVie
- Actelion
- Aiolos Bio
- Alkermes
- Arcutis Biotherapeutics
- Artelon
- Ascendis Pharma
- Avidity Biosciences
- BioXcel Therapeutics
- BridgeBio
- Boston Scientific
- Boundless Bio
- CARGO Therapeutics
- Centerview Partners
- Cerevel Therapeutics
- CeriBell
- CG Oncology
- Erasca
- Fractyl Health
- Fulgent Genetics
- GRAIL
- Gossamer Bio
- Homology Medicines
- Icosavax
- IDEAYA Biosciences
- Janssen Biotech
- Jnana Therapeutics
- Johnson & Johnson
- Laminar
- Metsera
- Mineralys Therapeutics
- Mirador Therapeutics
- Owlet
- PACS Group
- Phathom Pharmaceuticals
- Pharmacyclics
- Regeneron
- Revolution Medicines
- Rhythm Pharmaceuticals
- Sanofi
- Seres Therapeutics
- Sobi
- Tavo Biotherapeutics
- Tyra Biosciences
- Verona Pharma
- Zevra Therapeutics